{"id":33503,"date":"2026-05-10T06:55:29","date_gmt":"2026-05-10T06:55:29","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/33503\/"},"modified":"2026-05-10T06:55:29","modified_gmt":"2026-05-10T06:55:29","slug":"ai-startup-known-as-chatgpt-for-doctors-doubles-valuation-to-12b-in-latest-funding-round","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/33503\/","title":{"rendered":"AI startup known as \u2018ChatGPT for doctors\u2019 doubles valuation to $12B in latest funding round"},"content":{"rendered":"

OpenEvidence, an artificial intelligence startup known as \u201cChatGPT for doctors,\u201d clinched a funding round that doubled its valuation to a staggering $12 billion, the company told The Post.<\/p>\n

The Miami, Fla.-based startup, which trains its chatbots on data from top scientific journals, recently closed a $250 million financing round led by Thrive Capital and DST, according to a statement. CNBC earlier reported the financing round<\/a>.<\/p>\n

OpenEvidence kicked off its fundraising in February with $75 million from Sequoia at a $1 billion valuation. Just a few months later in October, the company\u2019s valuation jumped to $6 billion.<\/p>\n

\"\"<\/p>\n

OpenEvidence founder Daniel Nadler is a billionaire poet and techie. Sequoia Capital\/YoutTube<\/p>\n

The company has raised $700 million in less than a year from Google Ventures, Nvidia, Kleiner Perkins, David Sacks\u2019 Craft Ventures and Mayo Clinic, according to the press release.<\/p>\n

It was founded in 2022 by Daniel Nadler \u2013 a billionaire poet who sold his first company, Kensho Technologies, to Standard & Poor\u2019s for $700 million in 2018 \u2013 and Zachary Ziegler, previously a PhD student at Harvard studying AI.<\/p>\n

\u201cIf you only squint from a distance, OpenEvidence is \u2018ChatGPT\u2019 for doctors. If you look closely, it\u2019s a very different organism,\u201d Nadler told The Post in a statement.<\/p>\n

\u201cIt\u2019s built from the ground up specifically for doctors. It\u2019s free for doctors, but it\u2019s a pro tool,\u201d Nadler said. \u201cIt\u2019s trained on specialized medical content, such as the\u00a0New England Journal of Medicine\u00a0(through strategic partnerships).\u201d<\/p>\n

More than 40% of physicians already use the tool, Nadler claimed, and there is much more opportunity for growth in the health care sector \u2013 which accounts for nearly 20% of US gross domestic product with $5 trillion in yearly spending.<\/p>\n

\u201cHealth care is the largest segment of the real economy,\u201d Nadler told CNBC. \u201cPeople realize there could be a lot of winners in the space.\u201d<\/p>\n

Industry giants like OpenAI and Anthropic have already launched HIPAA-compliant versions of their chatbots, known as ChatGPT Health and Claude Healthcare.<\/p>\n

\"\"<\/p>\n

More than 50% of physicians already use OpenEvidence, Nadler claimed. Emily Norris\/peopleimages.com \u2013 stock.adobe.com<\/p>\n

Nadler said OpenEvidence\u2019s vast troves of quality health data put it a step ahead of the competition.<\/p>\n

\u201cWe\u2019ve already gathered hundreds of millions of real-world clinical consultations from verified physicians \u2013 that feedback loop is incredibly hard to replicate,\u201d he told CNBC.\u00a0<\/p>\n

\u201cEven if someone copied the playbook today, they\u2019d still be far behind because it\u2019s not just the partnerships, it\u2019s the real-world usage data.\u201d<\/p>\n

Nadler said his company is focused on building relationships with physicians.<\/p>\n

\u201cMost health care in America isn\u2019t happening at billion-dollar hospitals in New York or San Francisco,\u201d he said. \u201cIt\u2019s happening in small practices that don\u2019t have IT departments or budgets for expensive software.\u201d<\/p>\n

OpenEvidence relies on advertising for revenue \u2013 putting it ahead of the curve compared to rivals like OpenAI, which last week announced it would start testing ads on ChatGPT<\/a>.<\/p>\n

Nadler said the company raked in more than $100 million in annualized revenue last year, mostly from organic growth. A whopping 95% of new users hear about the app from other doctors, he said.<\/p>\n

\"\"<\/p>\n

Nadler said OpenEvidence\u2019s vast troves of quality health data put it a step ahead of the competition. No Priors\/YouTube<\/p>\n

The exec also said OpenEvidence is trying to be more disciplined than some companies that are \u201copenly planning to burn billions or tens of billions over the next several years\u201d \u2013 a dig at dominant large-language model makers.<\/p>\n

While AI giants have been on an acquisition spree, Nadler wants to keep OpenEvidence as an independent company, he said.<\/p>\n

He\u2019s also waiting for larger businesses like SpaceX, OpenAI and Anthropic to go public before considering an IPO for his own company.<\/p>\n

\u201cThere\u2019s an order to nature,\u201d Nadler told CNBC. \u201cFoundation model companies go public first \u2026That\u2019s how the internet played out, and that\u2019s how this cycle will play out, too.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"OpenEvidence, an artificial intelligence startup known as \u201cChatGPT for doctors,\u201d clinched a funding round that doubled its valuation…\n","protected":false},"author":2,"featured_media":33504,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[580,21404,2536,21405,157,10446],"class_list":["post-33503","post","type-post","status-publish","format-standard","has-post-thumbnail","category-openai","tag-chatgpt","tag-daniel-nadler","tag-doctors","tag-google-ventures","tag-openai","tag-thrive-capital"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/33503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=33503"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/33503\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/33504"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=33503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=33503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=33503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}